Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WG107
- Development stage
- Preclinical
- Lead developer
- Wingor Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
WG107 is an investigational stem cell therapy currently in preclinical development by Shenzhen Wingor Biotechnology. It is part of a broader pipeline of stem cell-based drug candidates (designated WG101 through WG108) developed by the company. While the specific cellular source and precise target for WG107 have not been disclosed, the therapy is being developed within the company's focus areas, which include immune-mediated diseases, chronic conditions, degenerative diseases, rare diseases, and oncology. As a cell therapy, it is designed to leverage the regenerative or immunomodulatory potential of stem cells to treat underlying pathological processes.
Beyond the preview
Go deeper on WG107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WG107.